INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Corporate insider
LX

Lin Xichen

CHIEF SCIENTIFIC OFFICERCIK 0001962926

EDGAR filingsOpen in network
Disclosed transactions22
Buys / sells0 / 7
Max Insider Score23
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
16
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$214K
4,539 sh
Sep 1, 2026Sep 2, 2026
traded Sep 1, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Structure Therapeutics Inc.CHIEF SCIENTIFIC OFFICER · Mar 5, 2026
0
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Option exercise · 10b5-1 plan
M
—
17.8K sh
Sep 1, 2026
Sep 2, 2026
traded Sep 1, 2026
+1d
SEC FORM 4

Evidence

12
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$60K
1,300 sh
Sep 1, 2026Sep 2, 2026
traded Sep 1, 2026
+1dSEC FORM 4

Evidence

0
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Derivative conversion · 10b5-1 plan
C—
5,939 sh
Sep 1, 2026Sep 2, 2026
traded Sep 1, 2026
+1dSEC FORM 4

Evidence

13
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$4,783
100 sh
Sep 1, 2026Sep 2, 2026
traded Sep 1, 2026
+1dSEC FORM 4

Evidence

0
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Derivative conversion · 10b5-1 plan
C—
17.8K sh
Sep 1, 2026Sep 2, 2026
traded Sep 1, 2026
+1dSEC FORM 4

Evidence

0
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Option exercise · 10b5-1 plan
M$6,058
17.8K sh
Sep 1, 2026Sep 2, 2026
traded Sep 1, 2026
+1dSEC FORM 4

Evidence

0
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Option exercise · 10b5-1 plan
M$4,018
11.8K sh
Aug 18, 2026Aug 19, 2026
traded Aug 18, 2026
+1dSEC FORM 4

Evidence

13
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$22K
400 sh
Aug 18, 2026Aug 19, 2026
traded Aug 18, 2026
+1dSEC FORM 4

Evidence

0
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Derivative conversion · 10b5-1 plan
C—
11.8K sh
Aug 18, 2026Aug 19, 2026
traded Aug 18, 2026
+1dSEC FORM 4

Evidence

0
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Derivative conversion · 10b5-1 plan
C—
3,939 sh
Aug 18, 2026Aug 19, 2026
traded Aug 18, 2026
+1dSEC FORM 4

Evidence

16
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$160K
3,020 sh
Aug 18, 2026Aug 19, 2026
traded Aug 18, 2026
+1dSEC FORM 4

Evidence

13
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$28K
519 sh
Aug 18, 2026Aug 19, 2026
traded Aug 18, 2026
+1dSEC FORM 4

Evidence

0
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
11.8K sh
Aug 18, 2026Aug 19, 2026
traded Aug 18, 2026
+1dSEC FORM 4

Evidence

3
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
23.6K sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

3
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Derivative conversion · 10b5-1 plan
C—
23.6K sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

0
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Derivative conversion · 10b5-1 plan
C—
7,878 sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

23
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$387K
7,878 sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

3
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Option exercise · 10b5-1 plan
M$8,036
23.6K sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

9
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Grant or award
A—
53.7K sh
Mar 19, 2026Mar 23, 2026
traded Mar 19, 2026
+4dSEC FORM 4

Evidence

17
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Grant or award
A—
43.4K sh
Mar 19, 2026Mar 23, 2026
traded Mar 19, 2026
+4dSEC FORM 4

Evidence

19
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Tax withholding
F$393K
18.7K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence